About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York State | 17,167 Studies Near You | Clareo Health

Clinical Trials LocationsNew York State

Clinical Trials in New York State

Discover 17,167 clinical trials near New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4081-4100 of 17,167 trials

RECRUITINGPhase 194 miles

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

NCT05504837

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Cystic Fibrosis

Krystal Biotech, Inc.12 participantsStarted Jun 2023

Gainesville, Florida, United States • Northfield, Illinois, United States • Hawthorne, New York, United States +2 more locations

COMPLETEDPhase 298 miles

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

NCT02998476

The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Incyte Corporation60 participantsStarted Mar 2017

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Tempe, Arizona, United States +67 more locations

Find Trials by Condition in New York State

Breast Cancerin New York State Lung Cancerin New York State Prostate Cancerin New York State Colorectal Cancerin New York State Melanomain New York State Leukemiain New York State Lymphomain New York State Pancreatic Cancerin New York State Ovarian Cancerin New York State Brain Cancerin New York State

Data from ClinicalTrials.govTerms

RECRUITING112 miles

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+13 more

Guardant Health, Inc.2,020 participantsStarted Sep 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Hot Springs, Arkansas, United States +54 more locations

RECRUITINGNA112 miles

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

NCT06094478

Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The "Door-In-Door-Out" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US "stand up" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.

Stroke, AcuteIschemic Stroke, AcuteHemorrhagic Stroke

University of Chicago900 participantsStarted Oct 2024

New Haven, Connecticut, United States • Miami, Florida, United States • Atlanta, Georgia, United States +4 more locations

COMPLETEDPhase 3112 miles

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

NCT04057573

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Non-segmental Vitiligo

Incyte Corporation344 participantsStarted Oct 2019

Gilbert, Arizona, United States • Fremont, California, United States • Irvine, California, United States +73 more locations

RECRUITING112 miles

STICH3C Cardiac Magnetic Resonance Observational Study

NCT07133984

STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death. This study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.

Ischemic Left Ventricle Systolic DysfunctionMultivessel Coronary Artery Disease

Weill Medical College of Cornell University200 participantsStarted Mar 2024

Brooklyn, New York, United States • Flushing, New York, United States • New York, New York, United States +6 more locations

TERMINATEDPhase 1112 miles

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

Solid TumorBreast CancerColon Cancer+2 more

Eli Lilly and Company94 participantsStarted Nov 2016

Miami, Florida, United States • Detroit, Michigan, United States • New York, New York, United States +8 more locations

COMPLETEDPhase 1112 miles

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04210219

The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in Part 2.

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Janssen Research & Development, LLC85 participantsStarted Jul 2020

New York, New York, United States • Tbilisi, Georgia • Chisinau, Moldova +12 more locations

RECRUITINGNA113 miles

Families Left Behind

NCT06854757

The United States is facing unprecedented rates of drug overdose deaths, profoundly impacting millions of families who are left to navigate their grief. Those bereaved by overdose experience a unique form of grief characterized by feelings of guilt, shame, and blame, which can worsen their suffering and deter them from seeking help. Individuals coping with overdose loss often endure more severe health consequences compared to those grieving non-drug related deaths, including prolonged grief disorder, substance use disorders, PTSD, depression, and suicidal thoughts. Moreover, bereaved individuals, particularly those with a history of substance use, may engage in risky behaviors as a means of coping, further exacerbating the risk of overdose and mortality within this vulnerable population. Peer grief support interventions have emerged as a promising approach to assist those experiencing such losses. To combat these outcomes, we are collaborating with Peer Community Support Partners (PSCP) in a novel practice-research partnership to implement the RIVER peer grief support model. Though RIVER has shown success in community settings, it has yet to be rigorously evaluated. In a three-aim approach, this study aims to assess the effectiveness of the RIVER model while also enhancing and engaging grievers with support resources via medical examiner offices (MEOs), which routinely contact families during death investigations. This research represents a pivotal advancement in addressing the needs of the overlooked bereaved community, aligning with the NIH's Helping to End Addiction Long-term (HEAL) initiative to develop effective strategies against the opioid crisis. Together, community engagement and rigorous research efforts aim to enhance support for those affected by the tragedy of drug overdose.

GriefGrief Disorder, ProlongedOverdose Accidental+1 more

RAND340 participantsStarted Jun 2025

Birmingham, Alabama, United States • San Diego, California, United States • Farmington, Connecticut, United States +1 more locations

COMPLETEDPhase 1/2153 miles

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

NCT03677154

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.

Diffuse Large B-cell Lymphoma

Hoffmann-La Roche188 participantsStarted May 2019

Birmingham, Alabama, United States • Santa Monica, California, United States • Fort Wayne, Indiana, United States +29 more locations

RECRUITINGPhase 1153 miles

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579

The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease.

Novartis Pharmaceuticals48 participantsStarted Nov 2023

Los Angeles, California, United States • Newport Beach, California, United States • Westwood, Kansas, United States +22 more locations

RECRUITINGPhase 3153 miles

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

NCT06832410

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Type 1 DiabetesKidney Transplant

Vertex Pharmaceuticals Incorporated10 participantsStarted Mar 2025

Philadelphia, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States • Madison, Wisconsin, United States +4 more locations

TERMINATEDPhase 1/2217 miles

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

NCT05109442

AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Advanced Solid Tumor

Affimed GmbH112 participantsStarted Nov 2021

Los Angeles, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +13 more locations

COMPLETED241 miles

Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies

NCT04919018

Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often identified as most problematic by patients and their families, and optimal, highly effective treatment regimens have not been established. The main objective of this project is to characterize and compare the upper airway phenotypes in individuals with confirmed diagnosis of PCD and PID, and to collect critical data to inform the design of future clinical trials of treatment of the upper airway diseases. The investigators anticipate that these investigations will discern the clinical, anatomical, and pathophysiological phenotypes of paranasal sinus disease in PCD and PID, identifying disease endpoints and biomarkers that differentiate these two overlapping disorders. Findings from these studies will also enhance our understanding of middle ear disease and associated hearing loss in a cross-sectional cohort of patients with PCD and PID. Ultimately, the long-term goal of our Consortium is to elucidate underlying phenotypes and genotypes of these diseases, potentially leading to novel therapeutics that will improve the lives of affected individuals. Given the COVID pandemic, certain procedures will have the option to be converted to telehealth visits to ensure compliance with local guidelines and participant safety.

Primary Ciliary DyskinesiaKartagener SyndromePrimary Immune Deficiency

University of North Carolina, Chapel Hill159 participantsStarted Jun 2021

St Louis, Missouri, United States • Chapel Hill, North Carolina, United States • Toronto, Ontario, Canada +1 more locations

COMPLETED241 miles

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

NCT04702243

The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).

Primary Ciliary DyskinesiaPrimary Immune DeficiencyKartagener Syndrome

University of North Carolina, Chapel Hill436 participantsStarted Dec 2020

Palo Alto, California, United States • Aurora, Colorado, United States • Bethesda, Maryland, United States +5 more locations

RECRUITING241 miles

The ReTAVI Prospective Observational Registry

NCT05601453

Patients with severe aortic stenosis (sAS) treated with transcatheter aortic valve implantation (TAVI) (increasingly younger \& lower risk pts) are experiencing SVD of the index THV and thus developing an indication for a redo-TAVI procedure. The evidence on redo-TAVI (where a transcatheter heart valve \[THV\] is implanted into another THV) is limited, with initial data showing acceptable safety as well efficacy in highly selected and limited populations. Aim is to evaluate short- and long-term data on patients undergoing transcatheter redo-TAVI procedures with THVs for failure of a previously implanted THV and to determine VARC-3 defined efficacy and safety at 30 days and functional outcome at 1 year, 3 years and 5 years.

Structural Valve DeteriorationStructural Valve DegenerationSymptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure+2 more

Institut für Pharmakologie und Präventive Medizin250 participantsStarted Sep 2023

Graz, Austria • Linz, Austria • Sankt Pölten, Austria +59 more locations

COMPLETED350 miles

Sickle Cell Disease, Hemechip

NCT03948516

Sickle cell disease is very common in Nigeria. Early diagnosis is important to prevent or reduce serious complications from the disease and to enable children stay healthy. To this end, the investigators would like to test a new, simple and quick device called the HemeChip to determine if it can detect whether or not someone has sickle cell disease. The investigators will compare the results obtained with the HemeChip with a standard method of diagnosing sickle cell disease known as Isoelectric focusing (IEF) or High Performance Liquid Chromatography (HPLC).If the investigators show that the new device can differentiate between children who have sickle cell disease and those who don't as successfully as the IEF or HPLC, they estimate a sharp increase in the use of this device in many countries especially in Africa due to its lower cost

Sickle Cell Disease

University Hospitals Cleveland Medical Center738 participantsStarted Jul 2017

Omaha, Nebraska, United States • Chapel Hill, North Carolina, United States • Cleveland, Ohio, United States +4 more locations

TERMINATEDPhase 1476 miles

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706

The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe substrates of cytochrome P450 (CYP) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with Active Crohn's disease (CD) or Ulcerative Colitis (UC).

Crohn DiseaseUlcerative Colitis

Janssen Research & Development, LLC28 participantsStarted Feb 2018

Cypress, California, United States • Miami Springs, Florida, United States • Durham, North Carolina, United States +13 more locations

COMPLETEDPhase 2507 miles

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

NCT04991753

The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).

Arthritis, Rheumatoid

Janssen Research & Development, LLC53 participantsStarted Oct 2021

Glendale, Arizona, United States • Mesa, Arizona, United States • Tucson, Arizona, United States +25 more locations

COMPLETEDPhase 1607 miles

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

NCT03424122

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

B-cell Lymphoma

Incyte Corporation50 participantsStarted Jul 2018

Tucson, Arizona, United States • Indianapolis, Indiana, United States • Las Vegas, Nevada, United States +18 more locations

PreviousPage 205 of 859Next

Diabetes

in New York State

Heart Diseasein New York State